Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18576414 | 0.78 | GSK3A (0.43) | ALDH1A1RAB9AMAPTGAAPOLB | |
| SCHEMBL5577987 | 0.76 | RAB9A (0.49) | ALDH1A1NPC1RAB9AMAPTGAA | |
| SCHEMBL18548441 | 0.73 | NPC1 (0.43) | ALDH1A1NPC1RAB9AMAPTGAA | |
| SCHEMBL14454806 | 0.71 | RPS6KA3 (0.44) | RPS6KA3ALDH1A1MAPTGAAKMT2A | |
| SCHEMBL4752792 | 0.70 | RPS6KA3 (0.47) | RPS6KA3MAPTGAAMAPK1HSD17B10 | |
| SCHEMBL5578045 | 0.67 | RPS6KA3 (0.44) | RPS6KA3MAPTGAAMAPK1HSD17B10 | |
| SCHEMBL14454801 | 0.67 | RPS6KA3 (0.41) | RPS6KA3 | |
| SCHEMBL14454844 | 0.65 | NPC1 (0.54) | ALDH1A1NPC1RAB9AMAPTPOLB | |
| SCHEMBL3499091 | 0.63 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9AMAPTGAA | |
| SCHEMBL3500620 | 0.63 | RPS6KA3 (0.41) | RPS6KA3ALDH1A1MAPTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138225-B2 | Amide compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10092584-B2 | Compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2017035360-A1 | COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035349-A1 | AMIDE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138225-B2 | Amide compounds for treatment of medical disorders | CFD, TFPI, CFH | RPS6KA3 693/4885ALDH1A1 3120/4885NPC1 1072/4885 |
| US-10092584-B2 | Compounds for the treatment of medical disorders | CFD, TFPI, CFH | RPS6KA3 1509/4885ALDH1A1 3300/4885NPC1 243/4885 |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | RPS6KA3 693/4885ALDH1A1 3120/4885NPC1 1072/4885 |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | CFD, TFPI, CFH | RPS6KA3 1509/4885ALDH1A1 3300/4885NPC1 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.